SG11201607421SA - METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION - Google Patents

METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION

Info

Publication number
SG11201607421SA
SG11201607421SA SG11201607421SA SG11201607421SA SG11201607421SA SG 11201607421S A SG11201607421S A SG 11201607421SA SG 11201607421S A SG11201607421S A SG 11201607421SA SG 11201607421S A SG11201607421S A SG 11201607421SA SG 11201607421S A SG11201607421S A SG 11201607421SA
Authority
SG
Singapore
Prior art keywords
translocation
nuclear factor
compound based
predicting toxicity
predicting
Prior art date
Application number
SG11201607421SA
Other languages
English (en)
Inventor
Daniele Zink
Sijing Xiong
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201607421SA priority Critical patent/SG11201607421SA/en
Publication of SG11201607421SA publication Critical patent/SG11201607421SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201607421SA 2014-03-17 2015-03-17 METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION SG11201607421SA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201607421SA SG11201607421SA (en) 2014-03-17 2015-03-17 METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201400705X 2014-03-17
SG11201607421SA SG11201607421SA (en) 2014-03-17 2015-03-17 METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION
PCT/SG2015/050039 WO2015142288A1 (en) 2014-03-17 2015-03-17 METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION

Publications (1)

Publication Number Publication Date
SG11201607421SA true SG11201607421SA (en) 2016-10-28

Family

ID=54145076

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607421SA SG11201607421SA (en) 2014-03-17 2015-03-17 METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION

Country Status (7)

Country Link
US (1) US20170082610A1 (ko)
EP (1) EP3120151A4 (ko)
JP (1) JP6491671B2 (ko)
KR (1) KR102353589B1 (ko)
CN (1) CN106461676B (ko)
SG (1) SG11201607421SA (ko)
WO (1) WO2015142288A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108885204B (zh) * 2015-11-20 2021-10-26 新加坡科技研究局 用于预测具有不同化学结构的异生物的细胞类型特异性毒性的基于高通量成像的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
JP3576491B2 (ja) * 1999-02-26 2004-10-13 セロミックス インコーポレイテッド 細胞ベースのスクリーニング用のシステム
AU2004218407A1 (en) * 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
ES2320056B1 (es) * 2005-11-02 2010-03-03 Universidad De Salamanca Uso de inhibidores del nf-kb in vitro para inducir la deplecion selectiva de linfocitos t alorreactivos, composiciones farmaceuticas derivadas y usos de las mismas.
WO2009126310A2 (en) * 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
NZ622427A (en) * 2009-10-30 2015-10-30 Univ North Carolina Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases

Also Published As

Publication number Publication date
WO2015142288A1 (en) 2015-09-24
CN106461676B (zh) 2019-07-05
US20170082610A1 (en) 2017-03-23
KR102353589B1 (ko) 2022-01-19
EP3120151A4 (en) 2017-08-09
KR20160134757A (ko) 2016-11-23
JP2017509340A (ja) 2017-04-06
JP6491671B2 (ja) 2019-03-27
CN106461676A (zh) 2017-02-22
EP3120151A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
IL247926B (en) A device that turns a liquid into a fine spray
IL246936A (en) Insulin administration method
IL246939A (en) Insulin administration method
DK3097265T3 (en) Well tools having magnetic shielding for magnetic sensor
PT3170730T (pt) Método de construção de uma estrutura em alto mar
GB2545360B (en) Method for manufacturing AMOLED backplane
PT2918629T (pt) Método para o fabrico de uma película respirável
GB2525396B (en) Method of operating a drilling system
GB2529888B (en) A method of image analysis
IL246889A0 (en) A method for measuring engagement
SG11201609350XA (en) Methods for inhibiting necroptosis
EP3116671C0 (en) METHOD FOR PRODUCING A COMPOSITE ROLLER
IL249868A0 (en) method
EP2894829C0 (de) Verfahren zum geschützten Übermitteln eines Datenobjekts
ZA201606324B (en) Method for diagnosing tuberculosis
PT3169844T (pt) Método para prevenir a formação de incrustação
GB2543334B (en) A method for providing an alert
GB201402036D0 (en) Method for determination of the status of a disease
GB2534534B (en) A method of storing data
GB201411799D0 (en) A computer-implemented method for providing a warning
KR101656145B9 (ko) 경로 정보 제공 방법
HK1210267A1 (en) Method for the measurement of a measurement object by means of -ray fluorescence
PL3164709T3 (pl) Identyfikacja związków modyfikujących fenotyp komórek
EP3164824C0 (en) METHOD FOR DETERMINING A MULTIFACTORIAL RISK SCORE OF DISEASE
SG11201607421SA (en) METHOD FOR PREDICTING TOXICITY OF A COMPOUND BASED ON NUCLEAR FACTOR-κB TRANSLOCATION